AISF position paper on HCV in immunocompromised patients

Italian Association for the Study of the Liver (AISF), Alfredo Marzano, Emanuele Angelucci, Marco Astegiano, Chiara Baratelli, Luigi Biancone, Paolo Bironzo, Giuseppina Brancaccio, Maurizia Rossana Brunetto, Raffaele Bruno, Patrizia Burra, Maria Giuseppina Cabras, Paolo Caraceni, Claudia Chialà, Maria Grazia Clemente, Agostino Colli, Bruno Daniele, Elisabetta De Gasperi, Vito Di Marco, Maria Chiara DittoStefano Fagiuoli, Clodoveo Ferri, Giovanni Battista Gaeta, Paolo Antonio Grossi, Barbara Imperatrice, Pietro Lampertico, Fabio Salvatore Macaluso, Salvatore Madonia, Massimo Marignani, Chiara Mazzarelli, Alberto Mella, Gabriele Missale, Simone Parisi, Luisa Pasulo, Massimo Puoti, Maria Rendina, Davide Ribaldone, Giuseppe Rossi, Pierluigi Toniutto, Alessandra Tucci, Pietro Vajro, Mauro Viganò, Riccardo Volpes, Anna Linda Zignego, Edoardo G. Giannini, Luca Miele, Francesco Paolo Russo, Salvatore Petta, Massimo Di Maio, Mario Rizzetto, Giuliano Torre

Research output: Contribution to journalArticlepeer-review

Abstract

This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.
Original languageEnglish
Pages (from-to)10-23
Number of pages14
JournalDig. Liver Dis.
Volume51
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • HCV
  • Immunocompromised patients
  • Organ transplant

Fingerprint

Dive into the research topics of 'AISF position paper on HCV in immunocompromised patients'. Together they form a unique fingerprint.

Cite this